new drug targets type diabetes metabolic syndrome 
insidious increase features metabolic syndrome obesity insulin resistance dyslipidaemia conspired produce worldwide epidemic type insulin-resistant diabetes mellitus current therapies disease developed absence defined molecular targets understanding disease pathogenesis emerging knowledge key pathogenic mechanisms impairment glucose-stimulated insulin secretion role lipotoxicity probable cause hepatic muscle resistance insulins effects glucose metabolism led host new molecular drug targets several validated genetic engineering mice preliminary use lead compounds therapeutic agents animals humans 
